Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target Raised to $39.00 at Cantor Fitzgerald

Posted by Geri Gentry on Sep 18th, 2026

Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Free Report) had its target price hoisted by stock analysts at Cantor Fitzgerald from $33.00 to $39.00 in a report issued on Friday, Benzinga reports. The firm currently has an “overweight” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price target suggests a potential upside of 168.97% from the company’s current price.

Several other analysts have also recently commented on the stock. TD Cowen lowered their target price on shares of Ultragenyx Pharmaceutical from $49.00 to $18.00 and set a “buy” rating for the company in a research note on Thursday, September 3rd. Evercore cut Ultragenyx Pharmaceutical from an “outperform” rating to an “in-line” rating and set a $16.00 price objective on the stock. in a report on Thursday, September 3rd. JPMorgan Chase & Co. downgraded Ultragenyx Pharmaceutical from an “overweight” rating to a “neutral” rating and lowered their price objective for the company from $80.00 to $36.00 in a research report on Thursday, September 3rd. Jefferies Financial Group dropped their target price on Ultragenyx Pharmaceutical from $77.00 to $28.00 and set a “buy” rating for the company in a research note on Thursday, September 3rd. Finally, Weiss Ratings upgraded Ultragenyx Pharmaceutical from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, July 9th. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $36.95.

View Our Latest Stock Report on Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Trading Up 12.6%

NASDAQ:RARE opened at $14.50 on Friday. Ultragenyx Pharmaceutical has a 12-month low of $12.73 and a 12-month high of $39.89. The firm has a market cap of $1.43 billion, a price-to-earnings ratio of -2.48 and a beta of 0.31. The company’s 50-day moving average is $24.26 and its two-hundred day moving average is $24.49.

Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported ($0.90) EPS for the quarter, topping analysts’ consensus estimates of ($1.22) by $0.32. The business had revenue of $214.00 million during the quarter, compared to the consensus estimate of $183.08 million. Ultragenyx Pharmaceutical had a negative net margin of 81.79% and a negative return on equity of 1,024.42%. The company’s quarterly revenue was up 28.5% compared to the same quarter last year. During the same period in the previous year, the firm posted ($1.17) earnings per share. On average, equities research analysts forecast that Ultragenyx Pharmaceutical will post -3.98 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

A number of large investors have recently bought and sold shares of RARE. BlackRock Inc. purchased a new position in shares of Ultragenyx Pharmaceutical in the 2nd quarter worth about $355,746,000. Assenagon Asset Management S.A. grew its holdings in shares of Ultragenyx Pharmaceutical by 1,030.4% during the 1st quarter. Assenagon Asset Management S.A. now owns 2,257,671 shares of the biopharmaceutical company’s stock worth $47,298,000 after purchasing an additional 2,057,951 shares during the period. Norges Bank purchased a new stake in shares of Ultragenyx Pharmaceutical during the 4th quarter worth about $29,004,000. Bank of America Corp DE acquired a new stake in Ultragenyx Pharmaceutical during the 2nd quarter worth approximately $38,347,000. Finally, Jefferies Financial Group Inc. acquired a new stake in Ultragenyx Pharmaceutical during the 2nd quarter worth approximately $31,040,000. Hedge funds and other institutional investors own 97.67% of the company’s stock.

Trending Headlines about Ultragenyx Pharmaceutical

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

Positive Sentiment: The FDA approved FAYUVI (rebisufligene etisparvovec-hopf) as the first approved treatment for pediatric Sanfilippo syndrome Type A, a fatal and progressive neurodegenerative disease with no prior treatment options. The therapy is designed to deliver a functional copy of the deficient SGSH gene. Reuters FDA approval article
Positive Sentiment: Clinical data supported full approval: treated patients showed a 23.5-point cognitive-score advantage versus an external natural-history group, with follow-up extending nearly eight years. Ultragenyx also received a Priority Review Voucher, which could accelerate a future drug candidate’s FDA review. Ultragenyx FAYUVI approval release
Positive Sentiment: FAYUVI is Ultragenyx’s second approved gene therapy and sixth FDA-approved product. The company expects shipments to qualified treatment centers within 30–60 days and has established its UltraCare program to help families navigate treatment and insurance access. Reports indicate a $3.95 million price, creating significant revenue potential if reimbursement and adoption are favorable. FAYUVI pricing article

About Ultragenyx Pharmaceutical

(Get Free Report)

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare and ultra-rare diseases. The company’s work includes therapies for genetic, metabolic and skeletal disorders, with an emphasis on conditions that have limited or no effective treatment options.

Ultragenyx’s marketed products include Crysvita (burosumab), used to treat certain forms of X-linked hypophosphatemia and tumor-induced osteomalacia; Dojolvi (triheptanoin), a medical food for long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab), a treatment for homozygous familial hypercholesterolemia.